- Drug development firm Sareum has reported a half-annual loss on ordinary activities for the six months ended 31 December 2020 of £0.55m.

It comes after the firm experienced a 2019 loss of £0.61m, however, the firm has welcomed positive product developments.

Cash at the period end was £1.30 million versus £1.80 million as of 30 June 2020 and £1.00 million as of 31 December 2019.

R&D Tax Credit of £0.13 million was received in January 2021, with the board focussing on the capital position of the company to ensure that the new products are adequately resourced

The development of TYK2/JAK1 inhibitors have been prioritised, and the company has welcomed substantial progress despite the challenges of the Covid-19 pandemic and has completed dose range-finding studies in two preclinical toxicology species.

Dr Tim Mitchell, CEO, commented: ‘We continue to actively engage with potential partners with a view to securing commercial licences for our TYK2/JAK1 programmes. We will, as usual, keep shareholders updated in this regard as appropriate.’

Story provided by